Advances in Molecular Mechanisms in Chronic Kidney Disease
A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Biomarkers".
Deadline for manuscript submissions: 30 November 2025 | Viewed by 98
Special Issue Editors
2. University Hospital of Burgos, Av. Islas Baleares 3, 09006 Burgos, Spain
Interests: real-world data research; clinical nephrology research
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Chronic kidney disease (CKD) affects more than 10% of the population worldwide, and its burden is increasing. Prevention, early detection and early treatment are key aspects to avoid its negative consequences on health, improve life expectancy, and reduce healthcare costs. In this context, exploring molecular pathways of the pathophysiology mechanisms involved in this disease state is becoming more important. The current concept of healthcare promotes the use of personalized interventions against diseases. In more practical terms, identifying individuals at high risk for developing CKD will help develop and adapt treatment strategies, with healing as a possible endpoint. The gut microbiota, genes other than those involved in autosomal dominant polycystic kidney disease (ADPKD), several enzymes and their substrates are the focus of clinical research. This Special Issue, “Advances in Molecular Mechanisms in Chronic Kidney Disease”, aims to garner original research articles and review articles that investigate the molecular pathways involved in CKD. New biomarkers for the disease should be addressed in order to improve the management of CKD.
Prof. Dr. Francisco Herrera-Gómez
Dr. María J. Izquierdo
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- chronic kidney disease
- end-stage kidney disease
- etiological diagnosis
- biomarkers
- personalized medicine
- humans
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
